These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Formation of DNA adducts and tumor growth delay following intratumoral administration of DTI-015. Bodell WJ; Giannini DD; Singh S; Pietronigro D; Levin VA J Neurooncol; 2003 May; 62(3):251-8. PubMed ID: 12777076 [TBL] [Abstract][Full Text] [Related]
5. Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant glioma. Rhines LD; Sampath P; DiMeco F; Lawson HC; Tyler BM; Hanes J; Olivi A; Brem H Neurosurgery; 2003 Apr; 52(4):872-9; discussion 879-80. PubMed ID: 12657184 [TBL] [Abstract][Full Text] [Related]
6. Interstitial chemotherapy of experimental brain tumors: comparison of intratumoral injection versus polymeric controlled release. Buahin KG; Brem H J Neurooncol; 1995 Nov; 26(2):103-10. PubMed ID: 8787852 [TBL] [Abstract][Full Text] [Related]
7. O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma. Rhines LD; Sampath P; Dolan ME; Tyler BM; Brem H; Weingart J Cancer Res; 2000 Nov; 60(22):6307-10. PubMed ID: 11103789 [TBL] [Abstract][Full Text] [Related]
8. Intralesionally implanted cisplatin plus systemic carmustine for the treatment of brain tumor in rats. Kong Q; Kleinschmidt-DeMasters BK; Lillehei KO J Surg Oncol; 1998 Oct; 69(2):76-82. PubMed ID: 9808509 [TBL] [Abstract][Full Text] [Related]
9. Levels and distribution of BCNU in GBM tumors following intratumoral injection of DTI-015 (BCNU-ethanol). Bodell WJ; Bodell AP; Giannini DD Neuro Oncol; 2007 Jan; 9(1):12-9. PubMed ID: 17018699 [TBL] [Abstract][Full Text] [Related]
10. Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Sipos EP; Tyler B; Piantadosi S; Burger PC; Brem H Cancer Chemother Pharmacol; 1997; 39(5):383-9. PubMed ID: 9054951 [TBL] [Abstract][Full Text] [Related]
11. [Study on drug delivery of the 3H-BCNU polylacties acid released agents on gliosarcoma]. Zhang YP; Xu XN; Wang JH; Lu G; Liu P; Su TF; Liu HS; Qi JB; Gao B Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2003 Sep; 15(9):568-9. PubMed ID: 12971860 [No Abstract] [Full Text] [Related]
12. Increased tumor cures using combined radiosurgery and BCNU in the treatment of 9l glioma in the rat brain. Khil MS; Kolozsvary A; Apple M; Kim JH Int J Radiat Oncol Biol Phys; 2000 May; 47(2):511-6. PubMed ID: 10802380 [TBL] [Abstract][Full Text] [Related]
13. Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma. Frazier JL; Wang PP; Case D; Tyler BM; Pradilla G; Weingart JD; Brem H J Neurooncol; 2003 Sep; 64(3):203-9. PubMed ID: 14558595 [TBL] [Abstract][Full Text] [Related]
14. The role of minocycline in the treatment of intracranial 9L glioma. Weingart JD; Sipos EP; Brem H J Neurosurg; 1995 Apr; 82(4):635-40. PubMed ID: 7897527 [TBL] [Abstract][Full Text] [Related]
15. Injection of chemotherapeutic microspheres and glioma. IV: Eradicating tumors in rats. Emerich DF; Winn SR; Bartus RT Cell Transplant; 2002; 11(1):47-54. PubMed ID: 12095219 [TBL] [Abstract][Full Text] [Related]
16. Synergistic cytotoxicity of the ribonucleotide reductase inhibitor didox (3,4-dihydroxy-benzohydroxamic acid) and the alkylating agent carmustine (BCNU) in 9L rat gliosarcoma cells and DAOY human medulloblastoma cells. Horvath Z; Höchtl T; Bauer W; Fritzer-Szekeres M; Elford HL; Szekeres T; Tihan T Cancer Chemother Pharmacol; 2004 Aug; 54(2):139-45. PubMed ID: 15133626 [TBL] [Abstract][Full Text] [Related]
17. Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model. Recinos VR; Tyler BM; Bekelis K; Sunshine SB; Vellimana A; Li KW; Brem H Neurosurgery; 2010 Mar; 66(3):530-7; discussion 537. PubMed ID: 20173548 [TBL] [Abstract][Full Text] [Related]
18. Effect of difluoromethylornithine on the antiglioma therapeutic efficacy of intra-arterial BCNU. Cohen AR; Pietronigro DD; Cravioto H; Flamm ES J Neurosurg; 1986 Nov; 65(5):671-8. PubMed ID: 3095505 [TBL] [Abstract][Full Text] [Related]
19. Levels of N7-(2-hydroxyethyl)guanine as a molecular dosimeter of drug delivery to human brain tumors. Bodell WJ; Giannini DD; Hassenbusch S; Levin VA Neuro Oncol; 2001 Oct; 3(4):241-5. PubMed ID: 11584893 [TBL] [Abstract][Full Text] [Related]
20. In vivo delivery of BCNU from a MEMS device to a tumor model. Li Y; Ho Duc HL; Tyler B; Williams T; Tupper M; Langer R; Brem H; Cima MJ J Control Release; 2005 Aug; 106(1-2):138-45. PubMed ID: 16167384 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]